Vaccine Effectiveness Drops from 90% to 50% Versus South Africa Variant

Clinical trial data on two COVID-19 vaccines are less protective versus the South Africa coronavirus variant.

Novavax reported midstage trial results on Thursday that showed its vaccine was 50% effective overall at preventing COVID-19 among people in South Africa. United Kingdom vaccine results were up to 89.3% effective at preventing COVID-19.

Pfizer and Moderna vaccines were around 95% in trials conducted before the new variants spread.

Pfizer Chief Executive Albert Bourla said there was “a high possibility” that emerging variants may eventually render the company’s vaccine ineffective.

Last week,

Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.

Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.

A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts.  He is open to public speaking and advising engagements.

Subscribe on Google News